Longeveron to receive Grant from the Maryland Stem Cell Research Fund

MIAMI, May 22, 2017 /PRNewswire/ -- Longeveron announced receiving a $750,000 grant from the Maryland Stem Cell Research Fund (MSCRF) to continue groundbreaking stem cell research.  Longeveron, a Miami based regenerative medicine company, will partner with the University of Maryland and Johns Hopkins University to conduct a clinical trial for Hypoplastic Left Heart Syndrome (HLHS), a rare and often fatal condition in infants caused by an underdeveloped heart.

According to Dr. Sunjay Kaushal, Director of Pediatric Cardiac Surgery at University of Maryland, and Site Investigator on this award, "We anticipate that the HLHS trial may be a game changing procedure to improve the ventricular performance for these HLHS babies that will improve their outcomes and allow them to live longer lives."

The MSCRF was established by the Governor and the Maryland General Assembly through the Maryland Stem Cell Research Act of 2006 to accelerate research using human stem cells and advance medical treatment. In a May 10 news release, Rabbi Avram Reisner, Chair of the Maryland Stem Cell Research Commission noted, "The awards announced are the first in our new Accelerating Cure initiative. They represent some of the most advanced regenerative medicine projects that are being undertaken. These awardees are at the leading edge of medical innovation and exemplify the purpose and mission of the Maryland Stem Cell Research Fund."

Longeveron Co-Founder & Chief Science Officer, Joshua M. Hare, M.D., who will serve as the Principal Investigator on this award stated, "Longeveron is honored to receive this competitive award from MSCRF to continue this important research to treat this life-threatening condition affecting infants."

About Longeveron 
Longeveron is a regenerative medicine therapy company founded in 2014. Longeveron's goal is to provide the first of its kind biological solution for aging-related diseases, and is dedicated to developing safe cell-based therapeutics to revolutionize the aging process and improve quality of life. The company's research focus areas include Alzheimer's disease, Aging Frailty and the Metabolic Syndrome. Longeveron produces LMSCs in its own state-of-the-art cGMP cell processing facility. www.longeveron.com

Contact:
Suzanne Liv Page
[email protected] 
305.909.0850

SOURCE Longeveron

Related Links

http://www.longeveron.com